Pharmaceuticals policy

FDA expands its support for states to advance implementation of produce safety activities

Retrieved on: 
Thursday, July 12, 2018
Health, Food and Drug Administration, United States Public Health Service, Pharmaceuticals policy, Food law, Food safety, FDA Food Safety Modernization Act

"Providing Americans with confidence in the safety of their fruits and vegetables is a major priority for the FDA, and states are a critical partner in implementing the Produce Safety Rule requirements that are designed to achieve these goals," said FDA Commissioner Scott Gottlieb, M.D.

Key Points: 
  • "Providing Americans with confidence in the safety of their fruits and vegetables is a major priority for the FDA, and states are a critical partner in implementing the Produce Safety Rule requirements that are designed to achieve these goals," said FDA Commissioner Scott Gottlieb, M.D.
  • To support our partners in this important work, the FDA is providing the funding to help states implement produce safety standards in their farming communities.
  • For the remainder of 2018, the FDA intends to support farmers through training and providing guidance on the rule's requirements in collaboration with the states and other partners.
  • The recipients of the cooperative agreements are also developing inventories of farms covered by the Produce Safety Rule to target outreach, education and inspection activities.

Seniors Overwhelmingly Support Pharmacy-Related Part D Reforms, Survey Says

Retrieved on: 
Thursday, July 12, 2018
Health, Pharmaceuticals policy, Healthcare reform in the United States, Federal assistance in the United States, Medicare, Presidency of Lyndon B. Johnson

Conducted in late June, the survey results indicate strong support among voters for measures that would increase stability in the popular Part D program while also lowering costs for seniors.

Key Points: 
  • Conducted in late June, the survey results indicate strong support among voters for measures that would increase stability in the popular Part D program while also lowering costs for seniors.
  • Voters consider Medicare Part D an effective program, and they are clear in their desire to ensure it is protected.
  • Reducing costs seniors endure due to deals and middlemen in the drug supply chain are also reforms that curry favor among voters.
  • While voters express concern regarding many PBM practices, they find the incentive to raise drug prices overwhelmingly suspect.

Farmmi, Inc. Enters into Contract to Develop Agricultural Products Quality Assurance and Traceability Software System

Retrieved on: 
Thursday, July 12, 2018
Barcodes, Forest certification, Pharmaceuticals policy, Radio-frequency identification, Software engineering, Traceability, Computing, Information and communications technology

Pursuant to the Contract, Evotrue is obligated to develop the software system and provide related services such as demand analysis, system installation, training, technical support, system upgrade as well as after-sales service.

Key Points: 
  • Pursuant to the Contract, Evotrue is obligated to develop the software system and provide related services such as demand analysis, system installation, training, technical support, system upgrade as well as after-sales service.
  • The Contract provides that the software system shall be installed and tested by August 15, 2018.
  • We are excited to work with Evotrue to develop a leading quality assurance and traceability software system for our agricultural products, as we endeavor to serve our customers with the best possible products."
  • In addition, Farmmi Liangpin Market, the Company's ecommerce platform, provides an opportunity for consumers to access locally sourced agricultural products.

HOYHEALTH Launches HoyRX, The New and Easy Way to Buy Medications at Low Cost

Retrieved on: 
Wednesday, July 11, 2018
Health, Pharmaceuticals policy, Clinical pharmacology, Medicinal chemistry, Pharmacy, Medical prescription, Drugs, Online pharmacy, Pharmaceutical Benefits Scheme

HoyRX is an easy-to-use medication voucher platform where consumers purchase their medications at low cost before going to the pharmacy.

Key Points: 
  • HoyRX is an easy-to-use medication voucher platform where consumers purchase their medications at low cost before going to the pharmacy.
  • Cost is the largest barrier to medication access and has direct consequences in the disruption of the health chain.
  • With HoyRX, consumers know the price of their generic medications as soon as they get their prescription, and pre-pay that low price in our platform.
  • HoyRX, the new and easy way to buy medications at low cost.

Deproteinized Calf Blood Extractives Report 2018: Global Market Opportunity Analysis & Forecast (2013-2022)

Retrieved on: 
Tuesday, July 10, 2018
Pharmaceutical industry in China, Pharmaceuticals policy, Science and technology in the People's Republic of China, Harbin, Heilongjiang, Pharmaceutical industry

3 Analysis on Major Deproteinized Calf Blood Extractives Manufacturers in China, 2013-2018

Key Points: 
  • 3 Analysis on Major Deproteinized Calf Blood Extractives Manufacturers in China, 2013-2018
    3.2 Jinzhou Ahon Pharmaceuticals Co., Ltd.
    3.3 Harbin Sanctity Pharmaceutical Co., Ltd.
    3.4 Jilin Connell Pharmaceutical Co., Ltd.
    3.5 Wuhan Humanwell Pharmaceutical Co., Ltd.
    3.6 Shenyang Xingqi Pharmaceutical Co., Ltd.
    3.7 Heilongjiang Jiangshi Pharmaceutical Co., Ltd.
    3.9 Zhaoke Pharmaceutical (Hefei) Co. Ltd.
    3.10 Changchun Tiancheng Pharmaceutical Co., Ltd.
    3.11 Fuan Pharmaceutical Group Hubei People's Pharmaceutical Co., Ltd.
    4 Prospects of Chinese Deproteinized Calf Blood Extractives Market, 2018-2022
    Chart Sales Value of Deproteinized Calf Blood Extractives in China, 2013-2017
    Chart Sales Value of Deproteinized Calf Blood Extractives in Parts of China, 2013-2017
    Chart Sales Volume of Deproteinized Calf Blood Extractives in China, 2013-2017
    Chart Sales Volume of Deproteinized Calf Blood Extractives in Parts of China, 2013-2017
    Chart Market Shares of Top 10 Deproteinized Calf Blood Extractives Manufacturers by Sales Value, 2013-2017
    Chart Market Share and Sales Value of Jinzhou Ahon's Deproteinized Calf Blood Extractives in China, 2013-2017
    Chart Market Share and Sales Value of Heilongjiang Jiangshi's Deproteinized Calf Blood Extractives in China, 2013-2017
    Chart Market Shares of Top 5 Deproteinized Calf Blood Extractives Manufacturers by Sales Volume, 2013-2017
    Chart Sales Value and Market Share of Deproteinized Calf Blood Extractives Injections, 2013-2017
    Chart Sales Value and Market Share of Deproteinized Calf Blood Extractives Gels, 2013-2017
    Chart Sales Value and Market Share of Deproteinized Calf Blood Extractives Eye Drops, 2013-2017
    Chart Prices of Jinzhou Ahon's Deproteinized Calf Blood Extractives in Several Chinese Cities, 2017-2018
    Chart Prices of Harbin Sanctity's Deproteinized Calf Blood Extractives in Several Chinese Cities, 2017-2018
    Chart Prices of Heilongjiang Jiangshi's Deproteinized Calf Blood Extractives in Several Chinese Cities, 2017-2018
    Chart Prices of Jilin Connell's Deproteinized Calf Blood Extractives in Several Chinese Cities, 2017-2018
    Chart Forecast on Sales of Deproteinized Calf Blood Extractives in China, 2018-2022

Healthcare Market in Indonesia: Opportunity & Challenge Forecast to 2022

Retrieved on: 
Tuesday, July 10, 2018
Pharmaceutical industry in China, Pharmaceuticals policy, Science and technology in the People's Republic of China

By Hospitals, Pharmaceuticals, Medical Devices and Clinical Laboratory, 2012-2017

Key Points: 
  • By Hospitals, Pharmaceuticals, Medical Devices and Clinical Laboratory, 2012-2017
    4.2.1.
  • By General and Specialty Hospitals, 2012-2016
    By Type of Specialty Hospitals on the Basis of Number of Hospitals and Beds, 2012-2015
    Case Study on Siloam Hospitals Located in Purwakarta, Java
    Demand Analysis for Siloam Hospitals Located in Purwakarta, Java
    4.10.
  • Indonesia Hospitals Future Outlook and Projections by Revenue, 2018-2022
    Vitamins and Dietary Supplements Market, 2012-2017
    5.2.2.
  • By Generic and Patented Drug, 2017
    By Type of Generic Drugs (Unbranded, Ethical and Free Sales), 2013 and 2017
    5.2.4.

Kiara Health's Vision to Transform Healthcare across Sub-Saharan Africa Applauded by Frost & Sullivan

Retrieved on: 
Tuesday, July 10, 2018
Health, Pharmaceuticals policy, Pharmaceutical industry, Pharmacology, Pharmacy, Pharmac

Kiara Health ensures that its products are optimally distributed across SSA by partnering with international device and pharmaceutical companies.

Key Points: 
  • Kiara Health ensures that its products are optimally distributed across SSA by partnering with international device and pharmaceutical companies.
  • Kiara Health has shown a strong dedication to lowering healthcare and medication costs by manufacturing generic pharmaceuticals locally.
  • "Overall, Kiara's vision and focus on solutions and values make it a worthy recipient of Frost & Sullivan's Visionary Innovation Leadership award."
  • Each year, Frost & Sullivan bestows this award upon the company that demonstrates excellence in growth and customer value.

Kiara Health's Vision to Transform Healthcare across Sub-Saharan Africa Applauded by Frost & Sullivan

Retrieved on: 
Tuesday, July 10, 2018
Health, Pharmaceuticals policy, Pharmaceutical industry, Pharmacology, Pharmacy, Pharmac

Kiara Health ensures that its products are optimally distributed across SSA by partnering with international device and pharmaceutical companies.

Key Points: 
  • Kiara Health ensures that its products are optimally distributed across SSA by partnering with international device and pharmaceutical companies.
  • Kiara Health has shown a strong dedication to lowering healthcare and medication costs by manufacturing generic pharmaceuticals locally.
  • "Overall, Kiara's vision and focus on solutions and values make it a worthy recipient of Frost & Sullivan's Visionary Innovation Leadership award."
  • Each year, Frost & Sullivan bestows this award upon the company that demonstrates excellence in growth and customer value.

Massachusetts Legislation Increases Drug Costs

Retrieved on: 
Friday, July 6, 2018
Health, Clinical pharmacology, Pharmacy, Pharmaceuticals policy, Drugs, Prescription drug, Pharmaceutical Care Management Association, Medical prescription, Pharmaceutical industry, Pharmacy benefit management

WASHINGTON, July 6, 2018 /PRNewswire-USNewswire/ -- Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement on health reform legislation in Massachusetts:

Key Points: 
  • WASHINGTON, July 6, 2018 /PRNewswire-USNewswire/ -- Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement on health reform legislation in Massachusetts:
    "The proposed legislation under consideration threatens to increase prescription drug costs by forcing payers to publicize their negotiating and discounting strategies with competing drugmakers.
  • The Federal Trade Commission and economists have repeatedly stated these types of proposals would raise costs bygiving drug companies inside information on their competitors' negotiations with insurers.
  • However, this legislation would undermine the tools employers, unions, and public programs use to reduce prescription drug costs and could promote tacit collusion among drug manufacturers, resulting in higher drug costs.
  • PBMs typically reduce prescription drug costs by 30 percent for more than 266 million Americans enrolled in private and public health plans.

Drug Manufacturers Continue to Significantly Increase Prescription Drug Prices

Retrieved on: 
Thursday, July 5, 2018
Healthcare reform in the United States, Federal assistance in the United States, Presidency of Lyndon B. Johnson, Health, Pharmaceuticals policy, Medicare Part D, Medicare, Federal Employees Health Benefits Program, Medicaid, Health insurance, Government, Pharmacy benefit management

WASHINGTON, July 5, 2018 /PRNewswire-USNewswire/ --Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement on reports of yet another round of massive price hikes by drug manufacturers.

Key Points: 
  • WASHINGTON, July 5, 2018 /PRNewswire-USNewswire/ --Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement on reports of yet another round of massive price hikes by drug manufacturers.
  • "News of recent price increases by drugmakers further confirms that the easiest way to lower costs would be for drug companies to lower their prices.
  • This news follows an Office of Inspector General, Health and Human Services report thatdebunked the myth that drugmakers have somehow been compelled to raise prices because of thediscounts and rebates health plans and PBMs demand to reduce overall costs."
  • PBMs administer prescription drug plans for more than 266 million Americans who have health insurance from a variety of sponsors including: commercial health plans, self-insured employer plans, union plans, Medicare Part D plans, the Federal Employees Health Benefits Program (FEHBP), state government employee plans, Medicaid plans, and others.